Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism
Bitzer, J.; Amy, J-Jacques.; Beerthuizen, R.; Birkhäuser, M.; Bombas, T.; Creinin, M.; Darney, P.D.; Vicente, L.Ferreira.; Gemzell-Danielsson, K.; Imthurn, B.; Jensen, J.T.; Kaunitz, A.M.; Kubba, A.; Lech, M.M.; Mansour, D.; Merki, G.; Rabe, T.; Sedlecki, K.; Serfaty, D.; Seydoux, J.; Shulman, L.P.; Sitruk-Ware, R.; Skouby, S.O.; Szarewski, A.; Trussell, J.; Westhoff, C.
European Journal of Contraception and Reproductive Health Care the Official Journal of the European Society of Contraception 18(3): 143-147
2013
ISSN/ISBN: 1473-0782 PMID: 23578274 DOI: 10.3109/13625187.2013.792637Document Number: 576412
Document emailed within 0-6 h
Related Documents
Bitzer, J.; Amy, J-Jacques.; Beerthuizen, R.; Birkhäuser, M.; Bombas, T.; Creinin, M.; Darney, P.D.; Vicente, L.Ferreira.; Gemzell-Danielsson, K.; Imthurn, B.; Jensen, J.T.; Kaunitz, A.M.; Kubba, A.; Lech, M.M.; Mansour, D.; Merki, G.; Rabe, T.; Sedlecki, K.; Serfaty, D.; Seydoux, J.; Shulman, L.P.; Sitruk-Ware, R.; Skouby, S.O.; Szarewski, A.; Trussell, J.; Westhoff, C. 2013: Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism journal of family planning and reproductive health care 39(3): 156-159Shapiro, S. 2013: Combined hormonal contraceptives and the risk of venous and arterial thromboembolism and cardiovascular death: misuse of automated databases Journal of Family Planning and Reproductive Health Care 39(2): 89-96
Van Vloten, W.A.; van Haselen, C.W.; van Zuuren, E.J.; Gerlinger, C.; Heithecker, R. 2002: The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea Cutis 69(4 Suppl): 2-15
Rosa, M.Inês.; Madeira, K.; Medeiros, L.Rosi. 2013: Can a meta-analysis that included articles with high heterogeneity appropriately evaluate the risk of venous thromboembolism in users of combined hormonal contraceptives containing drospirenone or desogestrel? European Journal of Contraception and Reproductive Health Care: the Official Journal of the European Society of Contraception 18(2): 137-139
Rosa, M.Inês.; Madeira, K.; Medeiros, L.Rosi. 2013: Can a meta-analysis that included articles with high heterogeneity appropriately evaluate the risk of venous thromboembolism in users of combined hormonal contraceptives containing drospirenone or desogestrel? European Journal of Contraception and Reproductive Health Care: the Official Journal of the European Society of Contraception 18(2): 137-139
Lidegaard, Øj.; Nielsen, L.H.; Skovlund, C.W.; Skjeldestad, F.E.; Løkkegaard, E. 2011: Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 Bmj 343: D6423
Maling, T.J. 1999: Third generation oral contraceptives and the risk of venous thromboembolism: management of the uncertainty New Zealand Medical Journal 112(1094): 305-307
Saguil, A. 2015: Risk of venous thromboembolism with use of combined oral contraceptives American Family Physician 91(5): 287-288
Hussain, M.; Kanamadi, R.D.; Saidapur, S.K. 1981: Effect of cyproterone acetate and cyproterone acetate + ascorbic acid on pars distalis of the toad Bufo melanostictus Indian Journal of Experimental Biology 19(11): 1061-1062
Newton, J.R. 1995: Classification and comparison of oral contraceptives containing new generation progestogens Human Reproduction Update 1(3): 231-263
Newton, J.R. 1995: Classification and comparison of oral contraceptives containing new generation progestogens Human Reproduction Update 1(3): 231-263
Rosenblatt, K.A.; Thomas, D.B. 1991: Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. the WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(6): 870-874
Rosenblatt, K.A.; Thomas, D.B. 1991: Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. the WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(6): 870-874
Rosenblatt, K.A.; Thomas, D.B. 1991: Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. the WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(6): 870-874
Shulman, L.P. 2011: The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives American Journal of Obstetrics and Gynecology 205(4 Suppl): S9-13
Shulman, L.P. 2011: The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives American Journal of Obstetrics and Gynecology 205(4 Suppl): S9-13
Shulman, L.P. 2011: The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives American Journal of Obstetrics and Gynecology 205(4 Suppl): S9-13
Plu-Bureau, Gève. 2015: Combined oral contraceptives and risk of venous thromboembolism: there is higher risk in new generations compared to second generations, but paradoxically not in norgestimate-containing-pills Evidence-Based Medicine 20(5): 189
Spona, J.; Huber, J. 1987: Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate Gynecologic and Obstetric Investigation 23(3): 184-193
Abrahamsson, L.; Hackl, H.; Sogn, J.; Stafsnes, H. 1979: Clinical results and hormonal aspects of the treatment of virilizing symptoms in women with cyproterone acetate Wiener Klinische Wochenschrift 91(4): 126-130